Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesoblast acquires Angioblast to bring adult stem cell platform under one roof

This article was originally published in Scrip

Executive Summary

Mesoblast of Australia is to acquire the remaining 67% stake in the privately held US firm Angioblast Systems that it does not already own, bringing commercial rights to an adult stem cell technology platform that both companies are working on under one umbrella.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC008775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel